H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on CalciMedica (CALC) to $16 from $20 and keeps a Buy rating on the shares. The firm believes the Phase 2b CARPO data “represent a significant step forward” in the clinical advancement of Auxora. It cites dilution from the equity raise for the target cut.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CALC: